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ScienceDirectCells from all domains of life encode energy-dependent trans-
membrane transporters that can expel harmful substances
including clinically applied therapeutic agents. As a collective
body, these transporters perform as a super-system that confers
tolerance to an enormous range of harmful compounds and
consequently aid survival in hazardous environments. In the
Gram-negative bacteria, some of these transporters serve as
energy-transducing components of tripartite assemblies that
actively efflux drugs and other harmful compounds, as well as
deliver virulence agents across the entire cell envelope. We draw
together recent structural and functional data to present the
current models for the transport mechanisms for the main classes
of multi-drug transporters and their higher-order assemblies.
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Introduction
What biological purpose do multidrug transporters
have?
Bacteria encode numerous multidrug transporters, and
while some are expressed constitutively, synthesis of
others is triggered by environmental factors, including
man-made drugs [1,2]. In the Gram-negative bacteria,
some of the transporters form large multi-protein
‘pump’ assemblies (to which we will return below),
and reflecting upon their considerable size, it seems
that the production of such molecular machines requires
substantial investment of energy and material. TheCurrent Opinion in Structural Biology 2015, 33:76–91 question naturally arises why such assemblies should
be expressed constitutively, or triggered by artificial
compounds such as drugs that might never have been
encountered in the wild. Perhaps the answer might lie in
part with the similarity of artificial drugs with abundant,
naturally occurring compounds for which the transporters
do have intrinsic preference. For example, it was shown
that Bacillus subtilis Blt multidrug transporter, which can
expel cationic amphiphiles, has a defined function in the
efflux of the natural polyamine spermidine [3]. Some
transporters are expressed to protect against nitrosative
damage during anaerobic respiration [4], or to efflux free
fatty acids [5] or gastrointestinal bile salts [6]. There is
growing appreciation that drug transporters are actually
required for growth and survival of pathogenic bacteria in
their intracellular hosts. In Mycobacterium tuberculosis, the
causative agent of clinical TB, efflux transporter genes
are induced during infection inside macrophages [7,8],
where they are likely to be involved into the efflux of host
protective molecules. Recent studies have identified a
mycobacterial transporter, Rv1258c, to be responsible for
macrophage-induced tolerance of the pathogen towards
the antibiotic rifampicin and for mycobacterial virulence
[7–9]. In addition to supporting survival in the presence
of toxic compounds, some of the transporters have been
found to export virulence factors and adhesion factors that
enable bacterial colonies to aggregate into protective
‘biofilm’ communities [10]. Thus, microbial multidrug
transporters can have specific physiological functions,
some of which might only be revealed when the organism
is in its natural habitat, rather than the nutrient-rich media
used in the laboratory [11]. Through their capacity to
expel diverse toxic compounds, efflux transporters con-
tribute to environmental fitness, and their ancient func-
tions have likely aided the capacity of microorganisms
to survive in competitive and hazardous niches. Under-
standing how such transporters work and how they might
be inhibited may be invaluable for treatment of many
threatening bacterial infections.
The main transporter families
Five families of trans-membrane transporters have been
well characterized thus far that are involved in active
efflux of antimicrobial agents. The family members
are widely distributed throughout all domains of life,
highlighting their biological importance (Figure 1) [12].
One such family comprises the ATP-binding cassette
(ABC) proteins, which are ‘primary-active’ in that theywww.sciencedirect.com
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Schematic of structures for five representatives of multidrug transporters. The molecules are aligned so that the cytoplasmic facing side is on the
bottom. The protomers (Sav1866 [13] and EmrE [14]) or symmetry related domains (EmrD [16] and PfMATE [67]) are colored light brown and
light grey; the protomers of AcrB trimer [100] are colored light blue, light brown and light grey. The substrates (with the exception of the EmrD
apo-structure) are shown as pink sphere. PDB codes: PfMATE: 3VVP; EmrD: 2GFP; EmrE: 3B5D; Sav1866: 2HYD; AcrB: 3AOD.use the free energy of ATP binding and/or hydrolysis to
catalyze drug extrusion [13]. The ‘secondary-active’ mul-
tidrug transporters are antiporters that couple drug efflux
to the influx of protons or sodium ions down electrochemi-
cal gradients; these define four distinct groups, namely
the major facilitator superfamily (MFS), small multidrug
resistance (SMR), resistance/nodulation/cell division
(RND), and multidrug and toxic compounds extrusion
(MATE) families (Table 1) [14,15,16,17,18]. Wheth-
er energized by electrochemical gradients or by the binding
and hydrolysis of nucleoside triphosphates, the transpor-
ters bear trans-membrane domains that switch conforma-
tions as they cycle through different substrate transport
states, as we will describe below.
ABC transporters
ABC transporters share a similar overall architecture, con-
sisting of two core units, namely, an intracellular nucleo-
tide-binding domain (NBD) dimer, which binds and
hydrolyses ATP at the dimer interface, and a cognate
membrane-domain (MD) dimer, which is embedded in
the plasma membrane and acts as a trans-membrane path-
way for substrates [19,20]. ABC transporters are organized
as either, homodimers or heterodimers Salmonella and the
NBD-MD subunit(s) may be encoded separately or as a
single polypeptide. The domains may be arranged with
an N-terminal MD and C-terminal NBD, or vice versa
[21,22]. Despite these variations, the family members
likely share a common transport mechanism.www.sciencedirect.com Crystal structures of the multidrug ABC exporter Sav1866
have revealed a dimer with the two closely associated
NBDs sandwiching the nucleotide (‘closed’), and the two
MD ‘wings’ facing towards the cell exterior [13]. Accord-
ingly, this conformation was termed ‘outward-facing’.
Nucleotide-bound crystal structures for MsbA from Sal-
monella typhimurium have been reported in a similar,
outward-facing conformation [23]. Moreover, MsbA from
Escherichia coli was crystallized in an inward-facing ‘open’
(open-apo) conformation in the absence of nucleotides,
where the NBDs were distant and the presumed sub-
strate-binding chamber in the MDs was facing the
cell interior [23]. The nucleotide-free structures of
murine and Caenorhabditis elegans multidrug resistance
P-glycoprotein ABCB1 were obtained in a similar in-
ward-facing conformation [24,25]. The crystal structures
for Vibrio cholerae MsbA [23] and the antimicrobial pep-
tide/multidrug transporter McjD from E. coli [26] show
closed structures that might represent an occluded tran-
sition state between the inward-facing and outward-
facing conformation. Many of these conformations have
also been observed individually using cryo-EM [27,28],
and are supported by data from biochemical and biophys-
ical experiments [29–38]. Cysteine cross-linking studies
first described the entire conformational cycle for a
single ABC exporter at major checkpoints of the ATPase
reaction under experimental conditions where the
exporter was transport-active in a biological membrane
[39–41].Current Opinion in Structural Biology 2015, 33:76–91
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Table 1
Structures of multidrug transporters*
Family Protein PDB code Substrates Resolution (A˚) Refs
ABC Sav1866 2HYD ADP 3.00 [13]
ABCB1 (mouse) 3G5U None 3.80 [24]
ABCB1 (C. elegans) 4F4C None 3.40 [25]
McjD 4PL0 AMP-PNP 2.70 [26]
MFS EmrD 2GFP None 3.50 [16]
YajR 3WDO None 3.15 [51]
MATE PfMATE 3VVN None 2.40 [67]
3VVO None 2.50
3VVR MaD5 3.00
NorM-VC 3MKT None 3.65 [15]
NorM-NG 4HUL Cs+ 3.81 [66]
4HUM Ethidium 3.49
4HUN Rhodamine 6G 3.59
DinF-BH 4LZ9 Rhodamine 6G 3.70 [65]
SMR EmrE 3B5D TPP+ 3.80 [14]
RND AcrB 1IWG None 3.50 [94]
2DHH None 2.80 [17]
2DRD Minocycline 3.10
2DR6 Doxorubicin 3.30
2GIF None 2.90 [18]
4DX5 Minocycline 1.90 [147]
4DX7 Doxorubicin 2.25
3AOC Erythromycin 3.34 [100]
3AOD Rifampicin, Minocycline 3.30
3W9H ABI-PP inhibitor 3.05 [144]
AcrB/AcrZ 4C48 None 3.30 [113]
MexB 3W9J ABI-PP inhibitor 3.15 [144]
2V50 None 3.00 [145]
MtrD 4MT1 None 3.54 [146]
* http://blanco.biomol.uci.edu/mpstruc/.Taken together, the available data support an ‘alternating
access’ model in which the substrate-binding pocket in the
MD [42] is exposed to the interior and exterior of the
cell as the transporter alternates between inward-facing
and outward-facing conformational states. The transition
between states occurs via an intermediate with a binding
pocket that is inaccessible to either side, and is governed by
ATP binding-associated NBD dimerization. ATP hydro-
lysis and ADP/Pi release-associated NBD dissociation
would finally reset the transporters to the inward-facing
conformation (Figure 2). The question whether the two
ATP sites in homodimeric ABC exporters hydrolyse the
nucleotide simultaneously, sequentially or in an alternat-
ing fashion has not yet been resolved in detail. It is also
unclear whether the inward-facing conformation with dis-
engaged NBDs is a generic state for all ABC exporters, or
whether in some ABC exporters the NBDs remain in close
contact throughout the catalytic cycle [43]. Furthermore,
one of two ATP sites is only active in ATP binding but not
in ATP hydrolysis in heterodimeric ABC exporters [44].
However, regardless of these variations in the detailed
mechanisms of ATP-dependent transport, the basic prin-
ciples of alternating access in ABC exporters are most likely
quite similar to those proposed for other classes of mem-
brane transporters, to which we now turn.Current Opinion in Structural Biology 2015, 33:76–91 MFS transporters
The MFS group is one of the largest families of second-
ary-active transporters. Most members are 400–600 amino
acid residues in length and possess 12 or 14 trans-mem-
brane (TM) helices. Crystal structures of prokaryotic and
eukaryotic MFS symporters, antiporters and uniporters
have been determined in different conformational states.
These transporters exhibit a high degree of structural
conservation, despite the limited sequence similarity,
distinct substrate specificities and coupling mechanisms.
The common structural architecture comprises two
domains, each composed of bundles of six helices. The
domains are related by a pseudo-twofold symmetry axis in
the membrane plane and are linked by a long cytoplasmic
loop or two TM helices [45–50].
The structures of representatives of the Drug:H+ Anti-
porter-1 (DHA1) group of MFS transporters have been
determined in occluded (EmrD) and outward open
(YajR) conformations, and comparing these structures
suggests a general mechanism for the conformational
change between the inward and outward states [16,51].
Crystal structures of a single protein captured in different
conformational states have provided a direct view of
conformational switch [45–48,52]. These observationswww.sciencedirect.com
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Schematic representations of the drug transport mechanism of ABC
efflux pumps. The transport cycle has been simplified to show only
three states: inward-facing, occluded state and outward-facing.and biochemical evidence suggest that MFS transporters
operate via a single binding site, alternating-access mecha-
nism, with the translocation pathway of the transport sub-
strate following the interface between the two six-helices
domains, and the substrate-binding cavity lies halfway into
the membrane. The rocker-switch type movement com-
prises consecutive and concerted conformational changes
of the two halves of the protein between inward open,
occluded and outward open states. The transport coupling
of MFS proteins involves sequential binding/releasing
of substrate/counterion, and this varies between family
members. The DHA1 transporter MdfA shows an indirect
competition mechanism between H+ and substrates
(Figure 3) [53], whereas both direct and indirect mecha-
nisms of competition might be relevant in LmrP [54,55].
Although MFS transporters generally function as mono-
mers, a recent crystal structure of plant NRT1.1 reveals an
unexpected homodimer with different affinity modes [49].
In Gram-negative bacteria, some MFS transporters form
tri-partite pumps with partner proteins, which directly
transport substrate from the inner membrane and cyto-
plasm to the cell exterior [56]. The MFS transporter EmrB,
which belongs to the DHA2 group and is a component of
a tripartite pump, was observed to form a dimer in complex
with another assembly component, EmrA [57].www.sciencedirect.com MATE transporters
MATE transporters function in the efflux of endogenous
cationic, lipophilic substances and xenobiotics [58–60],
and confer multidrug resistance on bacterial pathogens
and cancer cells [61,62]. Members of the MATE family
are thought to couple transport with influx of either Na+ or
H+, but ion coupling in this family is most likely more
complex [63]. The SLC47 family of MATE proteins are
involved in the efflux of important medications, and
disruption of MATE transporter activities can cause
severe changes in drug bioavailability and pharmacoki-
netics [64]. The MATE proteins range from 400 to
700 amino acids in length and have 12 putative trans-
membrane helices. Although they do no bear any appar-
ent conserved sequence motif, all MATE proteins share
40% sequence similarity, suggesting an overall con-
served structure and transport mechanism [15,58]. Struc-
tural information for several MATE transporters has
advanced our understanding of the mechanism of mem-
bers in this family, and suggests a rocker-switch mecha-
nism similar to that used by the MFS transporters
described in the previous section [15,65,66,67].
The structure of the PfMATE protein, which is an H+-
coupled MATE transporter, reveals an internal repeat
that is likely to have arisen from an ancient gene dupli-
cation event and comprises two bundles of six transmem-
brane helices (N-lobe TM1–TM6 and C-lobe TM7–
TM12) [67]. The bundles are related by pseudo-two-
fold symmetry along an axis normal to the membrane
plane and form a large internal cleft. In an outward-open
state, the cleft is open towards the extracellular side and
presents two non-equivalent portals within the lipid
bilayer. The hydrophobic central cleft can be divided
into two chambers, referred to as the N-lobe and C-lobe
cavities. A drug-binding pocket has been identified in the
N-lobe cavity located halfway into the membrane.
Thioether-macrocyclic peptide inhibitors of PfMATE
bind in this pocket, but are not transported possibly by
sterically preventing the rocker-switch motion of the N-
lobe and C-lobe. The question of how the movement
of protons and substrates is coupled is addressed by the
finding that protonation of Asp41 induces bending of
TM1 at Pro26, resulting in the collapse of the N-lobe
cavity that may displace the bound substrate into the
extracellular space [67]. A similar mechanism of (de)pro-
tonation-induced helix movement is seen in the AcrB
structure [68], described in the RND subsection below.
The NorM proteins are well-studied representatives of
MATE transporters. Recognizing a broad range of trans-
port substrates, NorM proteins confer resistance to dyes,
fluoroquinolones and aminoglycosides [69]. The structures
of NorM-VC and the related NorM-NG reveal similar
overall conformation to that of the H+-driven PfMATE
described above [15,66]. The structures of NorM-NG with
bound-substrates point to a multidrug-binding cavity thatCurrent Opinion in Structural Biology 2015, 33:76–91
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The indirect competition mechanism of MFS multidrug/proton antiport [53]. The substrate and proton bind to different residues in the transporter.
This mechanism involves a sequential process in which the substrate is bound after releasing of proton at the inside surface of the membrane,
and substrate is released before the binding of the proton at the outside surface of the membrane. Some MFS multidrug transporters show both
direct and indirect mechanisms of competition [54,55].is enriched in negative charges but rather limited hydro-
phobic moieties, implying reduced affinity for hydrophobic
substrates [66]. Since the substrate binding sites are located
near the membrane-periplasm interface, these structures
may represent intermediate states of transport. Substrates
might first bind to a cavity that is alternatively accessible
from both sides of the membrane bilayer, as shown in
PfMATE, and then move to a binding site near the
membrane-periplasm interface before being released, as
suggested for NorM-NG. Na+ and H+ play different roles
in the substrate transport by NorM-VC: Na+ was found to
stimulate ethidium binding, whereas ethidium binding
was found to drive H+ release [63]. Similar to PfMATE,
coupling ions might therefore play a role in the collapse
of the substrate-binding cavity to displace bound sub-
strates. In addition, coupling ions might directly drive
conformational transitions required for progression of the
transport cycle.
All the current MATE transporter structures have been
captured in an outward-open state, however, the binding/
releasing of H+/cation/substrates cause substantial rear-
rangement of the trans-membrane helices, such as TM7
and TM8, which may be important for the conformational
switch between outward-open and inward-open states
[15,65,66,67]. The elucidation of the structures captur-
ing the occluded and inward-open states and detailedCurrent Opinion in Structural Biology 2015, 33:76–91 biochemical analysis of transport mechanisms will be
critical for the understanding of the H+ and/or Na+/drug
antiport cycle of MATE transporters.
SMR transporters
The SMR family belongs to the drug/metabolite trans-
porter (DMT) superfamily, whose members are typically
composed of around 100–120 amino acid residues with
four predicted trans-membrane helices, and function in
general as homodimers. Some SMR family transporters
are composed of two dissimilar but homologous subunits
[70]. EmrE from E. coli is a H+:drug antiporter conferring
resistance to cations such as ethidium, proflavine, pyronin
Y, safranin O, and methyl viologen as well as to erythro-
mycin, sulfadiazine and tetracycline [71,72].
The structure of EmrE bound to tetraphenylphospho-
nium (TPP+), determined by X-ray crystallography and
cryo-EM, reveals an asymmetric, antiparallel homodimer
consisting of eight a-helix bundles, which are arranged
pairwise across the dimer interface [14,73]. This anti-
parallel topology within the dimer was confirmed by single-
molecule fluorescence-energy transfer experiments [74].
TPP+ binds in a chamber formed by TM1–3 from each
protomer. The dimer is favoured by inter-helical contacts
between TM4, which is nearly perpendicular to the
membrane [75–77]. The loops between TM3 and TM4www.sciencedirect.com
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strand, which holds TM4 close to the substrate-binding
chamber [77,78].
pt?>A single-site alternating access model suggests that
EmrE converts between inward-facing and outward-fac-
ing states to move substrates across a membrane barrier.
Trapping EmrE in a single state by cross-link abrogates
pump activity, suggesting the importance of conforma-
tional switching for the transport process [79]. The cou-
pling of protons and cationic substrates occurs through
competition for common binding to a conserved gluta-
mate in the TM1 (Glu14), with two protons exchanging
one polyaromatic cation [71,80–83]. The details of the
conformational exchange process were directly observed
in recent solution NMR studies, which show that the
conversion is achieved by conformational exchange of
protomers in the asymmetric EmrE dimer, so that the two
states are identical except that they have opposite orien-
tation in the membrane [74].
The structure and topology of SMR transporters have
long been controversial [70,84]. Since it has been shown
that a genetically-fused parallel dimer is active [85], as
well as fused anti-parallel dimers [86], both topoforms can
be given credibility, albeit that antiparallel dimers appear
to be more stable [87]. The topology of SMR proteins is
extremely sensitive towards modifications in the primary
sequence [88], making it difficult to attain the native form
of these proteins.
RND transporters
AcrB from E. coli is a well-studied representative of the
RND family of multidrug transporters. Recognizing a
broad range of transport substrates, it confers resistance
to numerous anti-microbial compounds including tetra-
cycline, chloramphenicol, b-lactams, novobiocin, fusidic
acid, nalidixic acid, and fluoroquinolones [89]; moreover,
it also transports sodium dodecylsulfate, Triton X-100,
detergent-like bile salts, cationic dyes, disinfectants [90],
and even nonpolar solvents [91,92]. The capacity of AcrB
to transport such a broad range of compounds raises the
intriguing structural puzzle of how this and other general
transporters recognize so many chemically distinct trans-
port substrates [93]. AcrB is a homotrimer and its proto-
mers bear a structural repeat as a result of an ancient gene
duplication event. AcrB has a 12-helix trans-membrane
domain and an extensive periplasmic portion comprising
porter and funnel domains [94,95]. The funnel domain is
composed of two subdomains, DN and DC. The porter
domain, located nearest to the inner membrane, can be
divided into four subdomains, PN1 and PN2, situated in
the N-terminal half between trans-membrane helices
TMH1 and TMH2, and the repeat-related subdomains
PC1 and PC2, which are located in the C-terminal half
between TMH7 and TMH8 (these domains are depicted
schematically in Figure 5b). The four subdomains pack towww.sciencedirect.com form two substrate-binding pockets, namely a proximal
(or access) and a distal (or deep) binding pocket separated
by a ‘switch-loop’ (Figure 4, lower panel). The pockets
are enriched in aromatic, polar and charged amino-acid
residues that form favourable interactions with the trans-
port substrates. The access pocket appears to favour
interactions with large substrates (or those with a large
minimal projection area [96]), like erythromycin, rifam-
picin or doxorubicin dimers. The deep binding pocket has
been shown by X-ray crystallography to harbour minocy-
cline or doxorubicin (as a monomer), and mutational as well
as molecular dynamics analyses predict binding of other
substrates [68,97–100,101]. These pockets might there-
fore each contribute to the broad substrate ‘polyspecificity’
of AcrB. Details of the pathways by which drugs enter AcrB
from different cellular compartments remain to be estab-
lished experimentally. One proposed pathway for drugs is
through the outer leaflet of the cytoplasmic membrane,
with entry through a TM8/TM9 groove entrance [95]. It
has also been proposed that substrate can enter from the
periplasm, and this might occur through the PC1/PC2 cleft
that is open from the periplasm and reaching in the access
pocket [95,102].
One fascinating aspect of AcrB is its loss of molecular
symmetry with drug binding, whereupon the three proto-
mers each adopt a distinct conformation, designated Loose
(L), Tight (T) and Open (O) (Figure 4). Compelling
structural and biochemical evidence indicates that these
conformations are consecutive steps within the transport
cycle, and correspond to ‘access’ (L), ‘binding’ (T), and
‘extrusion’ (O) states, in accord with the status of the
substrate-binding pocket [17,18,103]. During the trans-
port cycle, the PN1/PC2 repeat is rather rigid, while the
PN2/PC1 repeat undergoes cyclic changes internally due to
its function to bind substrates within the hydrophobic core
of the tandem. However, both PN1/PC2 and PN2/PC1
tandems undergo large conformational changes during cy-
cling through the three different states. The DN and DC
subdomains of each protomer form a funnel with an internal
diameter of about 30 A˚, and its conformation is largely
unchanged throughout the transport cycle of the pump.
The mechanism for drug transport involves a proton
translocation process, and evidence supports a proton
pathway involving residues D407, D408, and K940; these
are located in the middle of trans-membrane helices
TMH4 and TMH10 [104–106]. Recent crystallographic
and computational analyses show that the structural
repeats in the trans-membrane portion undergo a relative
rotation with respect to each other during the transport
cycle (rocking motion from the ‘access’ (L) to the ‘bind-
ing’ (T) state and a shearing motion from the ‘binding’
(T) to the ‘extrusion’ (O) state), which is linked with a
piston-like and tilting movements of TMH2 and TMH8
into the porter domain (Figure 5) [68]. Interestingly,
TMH2 connects to the flexible PN2/PC1 repeat, whereCurrent Opinion in Structural Biology 2015, 33:76–91
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Schematic representation of the ‘peristaltic’ transport mechanism of the RND transporter AcrB. Through coupling of proton and drug binding, the
AcrB trimer cycles through three conformational states with different shapes for the drug binding pocket: the ‘access’ (or ‘loose’ (L)), ‘binding’ (or
‘tight’ (T)) and ‘extrusion’ (or ‘open’ (O)) states. The upper panel depicts a cross section (two protomers of the AcrB/TolC trimers or AcrA hexamer)
through the full tripartite assembly, which is shown in more detail in Figure 6. TolC is at the top and AcrA is contacting TolC and AcrB. The middle
panel is a view of the AcrB trimer, from the perspective of the porter domain of the pump. The schematic in the lower panel depicts the passage
of drugs between the drug-binding pockets in a protomer; these are color coded to correspond to the three states shown in the other panels. In
the upper panel, the TolC is proposed to remain in an ‘open’ state throughout the conformational switches in AcrB.
Source: The figure is a modification of an image from Seeger et al. [18]; a similar model was also proposed by Murakami et al. [17].substrate binding occurs in the ‘binding’ (T) state,
and TMH8 is linked to the more rigid PN1/PC2
repeat. Binding of substrate to the PN2/PC1 unit causes
stabilization of the ‘binding’ (T) state and triggers theCurrent Opinion in Structural Biology 2015, 33:76–91 movement of TMH2 and formation of a chain of water
molecules leading from the periplasm to the titratable
residues D407 and D408 within the trans-membrane
domain. Upon protonation of these residues, the transitionwww.sciencedirect.com
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H+
Mechanistic detail of the proton coupling mechanism of the RND transporter, AcrB from E. coli (pdb entry: 4DX5). (a) Salt bridges form and break
in the different conformational states of AcrB. (b) The protonation states are linked to displacements of trans-membrane helices (TMH2 and
TMH8), which trigger changes in the pockets shown in Figure 4. The structures are for the E. coli AcrB. FD: funnel domain; PN1, PN2, PC1, PC2:
subdomains of the AcrB porter domain; TMD: trans-membrane domain.of the ‘binding’ (T) towards the ‘extrusion’ (O) state is
triggered. Protonation causes the shearing motion of the
structural repeats within the trans-membrane domain,
which not only disrupts the water chain and precludes
return of the protons towards the periplasm, but also
induces the movement of TMH8 and TMH2. Movement
of TMH8 causes the PN1/PC2 tandem to undergo a large
conformational change leading to the closure of the peri-
plasmic PC1/PC2 cleft, therefore sealing off the return
path of the drug towards the periplasm. Moreover, it
creates a new drug exit tunnel leading towards the funnel
domain (and eventually towards the exit duct). Concomi-
tantly, movement of TMH2, linked to the PN2 subdo-
main, causes the flexible PN2/PC1 to close its deep,
hydrophobic substrate-binding pocket, most likely in a
peristaltic fashion [107], squeezing the drug out. These
changes are concerted, and directly link the directionality
of proton influx and substrate efflux. The conformational
changes described above depict a rather simple model
that only focuses on a single protomer. Since AcrB is only
active as a trimer [108,109] and displays a highly coopera-
tive drug transport behaviour [110,111] inter-monomericwww.sciencedirect.com communication, or even communication with the AcrA
adaptor protein (described below) is likely involved in the
coupling of the three states leading to efficient drug efflux.
Modulators of RND transporters
In screens of the interacting partners of small proteins, a
49-residue protein was identified that interacts with the
AcrB protein [112]. Although not required for activity of
AcrB, this 49-residue protein, known as AcrZ (formerly
named YbhT) was found to impact on the sensitivity to
certain antibiotics, such as tetracycline, puromycin, and
chloramphenicol that are known substrates for AcrB.
Crystallographic analysis shows that AcrZ traverses the
TM domain of AcrB (Figure 6, bottom right) [113]. It is
not clear yet how AcrZ modulates the activity of the
transporter for a subgroup of antibiotics, but potential
mechanisms could be based on alterations in drug binding
or access to drug binding pockets. The interaction sur-
faces of AcrB and AcrZ are conserved in homologues, and
we speculate that other RND family members are likely
to have modulating partners that bind in the transmem-
brane groove in a similar fashion to AcrZ.Current Opinion in Structural Biology 2015, 33:76–91
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The cell envelope of Gram-negative bacteria and cooperative organization of transporters. The lower panel depicts the conformational switch for
the different classes of drug transporters during the transport process, as well as the pathway for transport substrates into the periplasm and then
exiting through the tripartite assembly as a ‘super-system’. The outer membrane (OM) is an asymmetric bilayer, with the lipids on the inner and
outer leaflets composed of phospholipids and glycolipids (principally lipopolysaccharides (LPS)), respectively. For Escherichia coli, the outer
membrane is anchored through abundant lipoproteins to the underlying peptidoglycan, which is composed of repeating units of the disaccharide
N-acetyl glucosamine-N-acetyl muramic acid, conferring mechanical robustness to the dual membrane system. The inner membrane layer (IM) is a
phospholipid bilayer, consisting largely of phosphatidylethanolamine, phosphatidylglycerol, and cardiolipin. The two membrane layers delimit an
aqueous cellular compartment densely packed with proteins, the periplasm, with a width estimated to be roughly 230 A˚, judging from electron
cryo tomography images.Tripartite multidrug efflux pumps in Gram-
negative bacteria span the cell envelope
The cell envelope of Gram-negative bacteria, a formida-
ble protective barrier, has three principal layers: the outer
membrane with an associated lipopolysaccharide (LPS)
coat on the cell exterior, the inner membrane that adjoins
the cytoplasm, and the peptidoglycan cell wall situated in
the space between the two membranes — the peri-
plasm — and which contributes to mechanical rigidity
(Figure 6) [114]. Moving molecules through this barrier
requires specialised machinery that helps to guide theCurrent Opinion in Structural Biology 2015, 33:76–91 transport substrates through the different layers [115–119].
Cytotoxic compounds, including clinical drugs, can be
driven from the cell by tripartite assemblies that span
the width of the envelope. Such assemblies include an
outer membrane protein, an inner membrane transporter,
and a periplasmic ‘membrane fusion’ protein that connects
the two trans-membrane components. The inner mem-
brane transporters typically belong to the MFS, RND, or
ABC families described above [57,113,120]. For the
RND type tripartite assemblies, transport substrates enter
the pump from the periplasm or from the periplasm-facingwww.sciencedirect.com
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moved into these locations by the action of ‘stand alone’
transporters that are not components of tripartite assem-
blies [121]. As a collective body, the tripartite and solitary
transporters can be considered as a super-system that
confers tolerance to an enormous range of harmful com-
pounds, including clinically applied antibiotics (Figure 6).
Structural information on the individual components of
the tripartite pump has advanced our understanding of
how the individual pump components might work in the
assembly. Recent electron microscopy structures of an
RND-type tripartite multidrug efflux pump have shown
how the components interact to form an operating machine
[113,122]. We will discuss each of the components in
the following sections before describing the full assembly.
Outer membrane proteins (OMP)
A representative outer membrane component of the
tripartite multidrug efflux pump is TolC from E. coli
(Figure 6, right). TolC assembles as a homotrimer with
three distinct structural regions: trans-membrane b-bar-
rel, periplasmic a-helical barrel, and a mixed a/b-fold also
in the periplasm and referred to as the equatorial domain
[123]. Like its partner RND transporter AcrB, the TolC
protomer bears a structural repeat, originating from an
ancient gene duplication. As a consequence, the tube-like
architecture of TolC has approximate six-fold symmetry.
The TolC tube has a large interior cavity that is mostly
solvent-filled with an average accessible interior diameter
of roughly 20 A˚ and is well shaped to form an exit duct,
except that it is tightly constricted at the end distal to the
outer membrane. Here, the effective diameter is only
3.9 A˚, which is much too small for the passage of
transport substrates. This constriction arises from the
inwardly curving trajectory of pairs of coiled-coil helices,
which meet at an apex and associate through salt bridges
near the constriction point. Carboxylates from conserved
side chains decorate the interior surface near this con-
striction and provide a ‘gating ring’ with selectivity for
cations [124,125]. Insight into how the channel opens has
been provided from crystal structures of partially opened
states of TolC [126,127] and the homologous Neisseria
gonorrhoeae MtrE (a component of the MtrC–MtrD–MtrE
tripartite pump) [128]; these reveal changes in the super-
helical trajectory of the coiled coils and breaking of the
gating salt bridges that favour the closed state. The
energy costs associated with these conformational
switches must be provided through interactions with
the other components of the efflux pump.
Membrane fusion proteins (MFP)
Crystal structures of MFP proteins from diverse bacterial
species reveal that many are comprised of four domains:
membrane-proximal, b-barrel, lipoyl, and a coiled-coil a-
helical hairpin (Figure 6, right) [129–131]. Some MFP
proteins lack the membrane proximal domain [132], whilewww.sciencedirect.com others have longer or shorter a-helical hairpin domains or
none at all [133], so there must be some diversity in the
way that these proteins assemble into active efflux pumps.
One feature that does seem to be general to the MFPs,
however, is that the inter-domain regions are flexible,
enabling the proteins to mould to accommodate their
partners in the efflux pumps. Another interesting aspect
of MFP proteins is that they can often self-associate into
oligomers, and these may mimic their organisation in the
full pump assembly.
Assembly of tripartite multidrug efflux pump AcrAB–
TolC
AcrAB–TolC is a paradigm of RND-type tripartite mul-
tidrug efflux pump. Du et al. developed a strategy to
stabilize the AcrABZ–TolC complex by fusion of the
pump components, and purified the full pump for single
particle cryo-EM assay [113]. A cryo-EM structure at
roughly 16 A˚ resolution shows that the AcrABZ-TolC
assembly comprises an AcrA hexamer, a TolC trimer,
three AcrZs, and an AcrB trimer (Figure 6). The recon-
structed shape and pseudoatomic model is in agreement
with a recently reported negative stain EM structure of
the pump prepared with a different engineering proce-
dure and without AcrZ [122].
The helical hairpins of AcrA pack to form bundles with
the ends of the helical portion of TolC [134], which
adopts a fully open state in the assembly. The importance
of this region of TolC is suggested by the observation
that, with a few residue mutations at the periplasmic tip,
outer membrane components could be exchanged be-
tween different tripartite pumps to make active assem-
blies [135,136]. The membrane proximal domain and
b-barrel domain of AcrA are involved in defined interac-
tions with AcrB. One protomer of AcrA bridges the upper
regions of subdomains PC1, PC2, and DC of AcrB, while
the adjacent protomer interacts with the upper regions of
PN2 and DN subdomains. The modeled docking of the
membrane-proximal domain onto the surface of AcrB is
consistent with the disruptive behaviour of mutants at
that interface [137].
The structure of CusBA complex, a homologue of AcrAB,
shows that the b-hairpin residues in the DN and DC
subdomains are involved in an interaction with the b-
barrel domains of the membrane-fusion protein [138].
These interactions were shown to be important for the
proper assembly of a hexameric AcrA suitable for presen-
tation to TolC [139]. The lipoyl domains principally
interact with each other and make no predicted interac-
tions with either AcrB or TolC.
The side-by-side arrangement of the b-barrel, lipoyl and
helical hairpin domains of the AcrA hexamer generates a
funnel-like structure with a sealed central channel along
the long molecular axis [113,140,141]. The bottom ofCurrent Opinion in Structural Biology 2015, 33:76–91
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AcrB. The channel is partially constrained near the mid-
dle of lipoyl domains and then runs from the helical
hairpin domains of the AcrA through the periplasmic
domain and transmembrane b-barrel of TolC to the cell
exterior. This conduit forms an exit pathway for efflux
substrates, which will be delivered into the channel
through successive opening and closing of ligand-binding
pockets in AcrB, adjacent to the apex of the funnel-
shaped periplasmic canyon.
Due to the sequential rotation mechanism of AcrB, de-
scribed above, three protomers adopt an extrusion state in
turn, which is ready to release a substrate molecule into
the funnel of the AcrB. Accordingly, TolC must adopt an
open state throughout the transport cycle, so that the
channel opening of TolC should be independent on the
conformational change of AcrB. Indeed, the cryo-EM
model, which represents the pump in a relaxed state,
shows that the interaction between AcrA and TolC can
directly open the channel. Although the surface area
contacted between the individual AcrA and TolC proto-
mers is not extensive, having six such surfaces pre-orga-
nised in an optimal orientation for interaction must
significantly boost the overall binding free energy. AcrB
provides a platform for the proper assembly of hexameric
AcrA suitable for presentation to TolC and opening of the
channel. The interaction between TolC and AcrA, in
turn, stabilizes the assembly of hexameric AcrA, account-
ing for the change in the proteolytic sensitivity of the
membrane-proximal domains of AcrA and MacA by TolC
[137,142]. The AcrAB–TolC pump is likely to be dynam-
ic, and the pump might accommodate the asymmetrical
cycling of AcrB during the transport through the inter-
domain flexibility of AcrA, allowing the TolC–AcrA in-
teraction to be maintained during the conformational
changes of AcrB throughout the substrate translocation
process.
Conclusions
Similar to other drug resistance mechanisms, efflux
pumps have likely existed from a very early stage in
the evolutionary history of bacteria [143], and they have
enabled this domain of life to occupy hazardous niches
and outwit competitors. We described here the RND-
based tripartite assembly, but there are also ABC and
MFS based assemblies that are currently not structurally
characterised; the interactions of the MFP and inner
membrane components are likely to differ markedly for
the different energy transducing classes, but all are likely
to share some architectural similarities in the organisation
of the MFP and outer membrane components. Structural
data for the RND based pumps has provided some insight
into how the periplasmic portions of the ABC and MFS
based pumps may be organised. Related tripartite assem-
blies that are energised by an ABC transporter drive
virulence determinants of pathogenic bacteria acrossCurrent Opinion in Structural Biology 2015, 33:76–91 the cell envelope, such as adhesins, toxins, or other
proteins that are important for the colonization and infec-
tion of human and animal cells [2]. These protein trans-
locators, known as type I secretion systems, also use TolC
as an exit duct.
In Gram-negative bacteria, RND family drug transporters
mostly assemble with their partner proteins to form
tripartite pumps, which acquire substrates from the outer
leaflet of inner membrane and periplasm and efflux to the
cell exterior. In contrast, members of the other four
families of drug transporters usually function as indepen-
dent units in the inner membrane to translocate sub-
strates across the membrane bilayer. It is likely that these
transporter systems cooperate with RND-type tripartite
efflux pumps to deliver substrates across the entire cell
envelope as part of a larger drug efflux super-organization.
In this scenario, it is envisaged that the drugs are trans-
ported by the ‘unitary’ transporters into the periplasm or
outer leaflet of the plasma membrane, where they are
intercepted and expelled by the RND tripartite assem-
blies (Figure 6) [121].
Multidrug transporters have many properties that are
unexplained at present. For example, the capacity of
RND and ABC exporters to transport a broad range of
compounds raises the question whether there might be
some trade-off between substrate recognition and trans-
port efficiency. The answer awaits accurate experimental
measurements of the amount of metabolic energy re-
quired to transport numerous types of substrates. The
growing structural information on these systems may also
guide rational approaches to design compounds that
interfere with the function of the transporters [144] or
the assembly of the pumps. The recently discovered
PACE family transporters are also involved in multidrug
efflux and are likely to be structurally distinct [148,149].
Characterizing the structrure and function is another key
research question in the field. There is clearly much
remaining to be discovered regarding these fascinating
nanomachines.
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Note added in proof
A recent study reports the crystal structure of E. coli MdfA
in complexes with chloramphenicol, deoxycholate and
LDAO. The structures reveal how multi-drug resistance
MFS transporters engage ligands in the inward-facing
conformational state [150]. Also reported are crystal struc-
tures of the polypeptide processing and secretion trans-
porter from Clostridium thermocellum; this is an ABC
transporter related to the type I secretion system of Gram
negative bacteria. The structures capture two different
conformations and illustrate the proposed transport cycle
for another ABC exporter [151].www.sciencedirect.com
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